Oncoinvent ASA Income Statement

Financials in millions NOK. Fiscal year is January - December.

Millions NOK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	23.04	2.73	0.06	0.07	0.36
Other Revenue	5.03	5.37	5.73	6.22	10.72
Revenue	28.07	8.1	5.79	6.28	11.08
Revenue Growth (YoY)	246.40%	39.95%	-7.85%	-43.31%	6.80%
Cost of Revenue	-	-	-	-	0.9
Gross Profit	28.07	8.1	5.79	6.28	10.19
Selling, General & Admin	69.72	51.44	55.74	47.34	37.56
Other Operating Expenses	105.43	83.13	86.22	61.57	48.66
Operating Expenses	186.4	149.12	153.22	116.89	91.01
Operating Income	-158.33	-141.02	-147.43	-110.61	-80.83
Interest Expense	-0.84	-0.08	-0.01	-0.01	-0.01
Interest & Investment Income	-	1.34	4.41	4.44	0.75
Currency Exchange Gain (Loss)	-	-0.45	-0.6	-0.11	-
Other Non Operating Income (Expenses)	4.1	-	-	-	-0.21
Pretax Income	-155.07	-140.2	-143.62	-106.28	-80.29
Net Income	-155.07	-140.2	-143.62	-106.28	-80.29
Net Income to Common	-155.07	-140.2	-143.62	-106.28	-80.29
Shares Outstanding (Basic)	124	1	0	0	0
Shares Outstanding (Diluted)	124	1	0	0	0
Shares Change (YoY)	13348.78%	374.39%	0.27%	-2.42%	38.93%
EPS (Basic)	-1.25	-151.99	-738.62	-548.04	-404.00
EPS (Diluted)	-1.25	-151.99	-738.62	-548.04	-404.00
Free Cash Flow	-129.99	-89.75	-164.94	-93.17	-
Free Cash Flow Per Share	-1.05	-97.29	-848.27	-480.45	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	91.92%
Operating Margin	-564.07%	-1740.31%	-2546.20%	-1760.48%	-729.27%
Profit Margin	-552.46%	-1730.24%	-2480.50%	-1691.55%	-724.43%
Free Cash Flow Margin	-463.11%	-1107.55%	-2848.72%	-1482.94%	-
EBITDA	-149.8	-131.81	-139.84	-105.82	-76.04
D&A For EBITDA	8.54	9.2	7.59	4.79	4.79
EBIT	-158.33	-141.02	-147.43	-110.61	-80.83
Revenue as Reported	28.07	8.1	5.79	6.28	11.08
Advertising Expenses	-	-	-	-	0.09

Source: S&P Global Market Intelligence. Standard template. Financial Sources.